Fei Jiang

Fei Jiang is an experienced executive in the healthcare investment and pharmaceutical industries, currently serving as Chief Investment Officer for Greater China at 康哲药业有限公司 since January 2022. Prior roles include Managing Director at 洪泰基金, Executive Director positions at Sinopharm Capital and Zhongnuo Venture, and Director of Business Development and R&D at 3SBio Inc. Fei has a solid background in private equity and venture capital investment, strategic alliance management, and biopharmaceutical R&D, with expertise in drug development, due diligence, and deal negotiation. Educational qualifications include a Ph.D. in Chemical Engineering from Syracuse University and a B.Sc. in Chemical Engineering from East China University of Science and Technology.